

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):
November 17, 2005

USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)

Commission File No. 0-21116

Utah
(State or other jurisdiction of
incorporation)

87-0500306
(IRS Employer Identification
Number)

3838 West Parkway Boulevard
Salt Lake City, Utah 84120
(Address of principal executive offices, Zip Code)

Registrant's telephone number, including area code: (801) 954-7100

Former name or former address, if changed since last report: Not Applicable

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

- Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On November 17, 2005, USANA Health Sciences, Inc. issued a press release announcing that its board of directors has authorized an additional \$50 million for share repurchases of its outstanding common stock. The release also announced that share repurchases will be made from time-to-time, in the open market, through block trades or otherwise, and will be based on market conditions, the level of cash balances, general business opportunities, and other factors. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The company will also post this document on its corporate website, www.usanahealthsciences.com, under the "investors" link.

Item 9.01 Financial Statements and Exhibits (furnished herewith)

(d) Exhibits

Exhibit 99.1 Press release issued by USANA Health Sciences, Inc. dated
November 17, 2005

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

USANA HEALTH SCIENCES, INC.

By: /s/ Gilbert A. Fuller

Gilbert A. Fuller,
Chief Financial Officer

Date: November 18, 2005

3

Exhibit 99.1

USANA Increases Authorized Share Repurchase Program by an Additional \$50 Million

SALT LAKE CITY--(BUSINESS WIRE)--Nov. 17, 2005--USANA Health Sciences, Inc. (NASDAQ: USNA) today announced that its board of directors has authorized an additional \$50 million for share repurchases of its outstanding common stock.

Repurchases will be made from time to time, in the open market, through block trades or otherwise. The number of shares to be purchased and the timing of purchases will be based on market conditions, the level of cash balances, general business opportunities, and other factors.

Prior to this authorization USANA had completed all share repurchases previously authorized by the board. During 2005, the Company has repurchased approximately 926,000 shares for a total investment of \$40 million.

USANA had 18,561,648 common shares outstanding as of November 15, 2005.

About USANA

USANA develops and manufactures high quality nutritional and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, Japan, Taiwan, South Korea, Singapore, Mexico, the Netherlands, and the United Kingdom. More information on USANA can be found at <http://www.usanahealthsciences.com>.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, and uncertainties associated with our planned international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

CONTACT: USANA Health Sciences, Inc.
Investor Relations
Riley Timmer, 801-954-7100
investor.relations@us.usana.com